Ningping Zhang

180 Fenglin Road
Zhongshan, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Machine Learning Models Using Hospital Admission Characteristics Do Not Optimally Predict Nosocomial Infection Development in a Global Cirrhosis Cohort.

Machine Learning Models Using Hospital Admission Characteristics Do Not Optimally Predict Nosocomial Infection Development in a Global Cirrhosis Cohort.

Journal: The American journal of gastroenterology

Published: February 01, 2026

Association between cholesterol and liver injury risk in solid cancer patients treated with PD-1 inhibitors: evidence from two cohort studies.

Association between cholesterol and liver injury risk in solid cancer patients treated with PD-1 inhibitors: evidence from two cohort studies.

Journal: BMC cancer

Published: January 12, 2026

Development and validation of a machine learning-based clinical prediction model for monitoring liver injury in patients with pan-cancer receiving immunotherapy.

Development and validation of a machine learning-based clinical prediction model for monitoring liver injury in patients with pan-cancer receiving immunotherapy.

Journal: International journal of medical informatics

Published: May 13, 2025

Risk Factors of Immune-Mediated Hepatotoxicity Induced by Immune Checkpoint Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis.

Risk Factors of Immune-Mediated Hepatotoxicity Induced by Immune Checkpoint Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis.

Journal: Current oncology (Toronto, Ont.)

Published: September 25, 2024

New advances in novel pharmacotherapeutic candidates for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) between 2022 and 2024.

New advances in novel pharmacotherapeutic candidates for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) between 2022 and 2024.

Journal: Acta pharmacologica Sinica

Published: September 14, 2024

Tofacitinib for the treatment of immune-related adverse events in cancer immunotherapy: a multi-center observational study.

Tofacitinib for the treatment of immune-related adverse events in cancer immunotherapy: a multi-center observational study.

Journal: Journal of translational medicine

Published: June 17, 2024

Clinical characteristics and prognosis of liver injury induced by immune checkpoint inhibitors in patients with malignancies: A real-world retrospective study.

Clinical characteristics and prognosis of liver injury induced by immune checkpoint inhibitors in patients with malignancies: A real-world retrospective study.

Journal: British journal of clinical pharmacology

Published: February 28, 2024

Morphology of immune-mediated hepatitis: A comparison between immune checkpoint inhibitor therapy and combined immune checkpoint inhibitor/anti-angiogenic therapy.

Morphology of immune-mediated hepatitis: A comparison between immune checkpoint inhibitor therapy and combined immune checkpoint inhibitor/anti-angiogenic therapy.

Journal: Annals of diagnostic pathology

Published: August 18, 2023

Interferon regulatory factor family influences tumor immunity and prognosis of patients with colorectal cancer.

Interferon regulatory factor family influences tumor immunity and prognosis of patients with colorectal cancer.

Journal: Journal of translational medicine

Published: March 19, 2021

Dampened VEPH1 activates mTORC1 signaling by weakening the TSC1/TSC2 association in hepatocellular carcinoma.

Dampened VEPH1 activates mTORC1 signaling by weakening the TSC1/TSC2 association in hepatocellular carcinoma.

Journal: Journal of hepatology

Published: September 04, 2019

M2-polarized tumor-associated macrophages promote epithelial-mesenchymal transition via activation of the AKT3/PRAS40 signaling pathway in intrahepatic cholangiocarcinoma.

M2-polarized tumor-associated macrophages promote epithelial-mesenchymal transition via activation of the AKT3/PRAS40 signaling pathway in intrahepatic cholangiocarcinoma.

Journal: Journal of cellular biochemistry

Published: June 04, 2019

CAPS1 Suppresses Tumorigenesis in Cholangiocarcinoma.

CAPS1 Suppresses Tumorigenesis in Cholangiocarcinoma.

Journal: Digestive diseases and sciences

Published: May 20, 2019

Showing 1-12 of 13

Last Updated: 09/26/2026